EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Next-Generation Sequencing (NGS) in non-small cell lung carcinoma: A real-world experience in the public health system of Galicia (Northwest Spain)

Ihab Abdulkader-Nallib, José Manuel Cameselle-Teijeiro iD, Iván Lesende-Rodríguez iD, Raquel Pérez-Becerra, José Ramón Antúnez-López, Jorge García-González iD, Luis León-Mateos iD, María Sánchez-Ares iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0326336 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Ihab Abdulkader-Nallib und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Clinical University Hospital of Santiago de Compostela, Health Research Institute of Santiago de Compostela, Galician Health…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, High-Throughput Nucleotide Sequencing, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, The Health Knowledge Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The validation of several predictive biomarkers has improved the clinical outcomes of non-small cell lung carcinoma (NSCLC) patients. Single tests do not cover the mutational co-occurrences, so they do not detect other alterations, which in many cases are responsible for disease progression. We describe the development and implementation of a customized next generation sequencing (NGS) panel. We analyzed 236 formalin-fixed paraffin-embedded (FFPE) NSCLC samples from the Clinical University Hospital of Santiago de Compostela (Galicia, Northwest Spain) in 2020. Detection of EGFR , KRAS , NRAS , BRAF mutations and ALK , ROS1 rearrangements were determined by real-time polymerase chain reaction (RT-PCR), immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). These results were compared with those obtained by the NGS panel to evaluate the performance of the NGS method and to identify potential novel mutations. Ten discrepancies between NGS and the orthogonal methods were found: 2 cases in the EGFR gene, 1 in the KRAS gene, 5 in the BRAF gene and 2 in the ALK gene. The most prevalent pathogenic alterations detected by NGS were: TP53 (48.7%), KRAS (23.7%), STK11 (9.7%), EGFR (8.5%), PIK3CA (5.5%), CDKN2A (4.7%), BRAF (3.4%) and MET exon skipping 14 (3%); rearrangements were found in ALK and RET (3.5% and 1.7%, respectively). 41.5% of NSCLC patients are harbored co-occurring mutations. Our findings confirmed the robustness, sensitivity and specificity of NGS compared to conventional approaches. NGS has a role not only in the detection of actionable alterations (including concurrent mutations), but also in stratifying patients for therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungHigh-Throughput Nucleotide SequencingLung NeoplasmsHumansSpainFemaleMaleMiddle AgedMutationAgedAdultAnaplastic Lymphoma KinaseErbB ReceptorsAged, 80 and overProto-Oncogene Proteins B-rafBiomarkers, TumorProto-Oncogene Proteins p21(ras)Proto-Oncogene Proteins

Substanzen

Anaplastic Lymphoma KinaseErbB ReceptorsALK protein, humanProto-Oncogene Proteins B-rafBiomarkers, TumorProto-Oncogene Proteins p21(ras)BRAF protein, humanEGFR protein, humanKRAS protein, humanProto-Oncogene Proteins

Autor:innen und Institutionen

  • Department of Pathology, Clinical University Hospital of Santiago de Compostela, Health Research Institute of Santiago de Compostela, Galician Healthcare Service (SERGAS), Santiago de Compostela, Spain.
  • School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain.
  • University of A Coruña, A Coruña, Spain.
  • Department of Medical Oncology, Clinical University Hospital of Santiago de Compostela, Galician Healthcare Service (SERGAS), Santiago de Compostela, Spain.
  • ONCOMET, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
  • The Spanish Biomedical Research Centre in Cancer (CIBERONC), Madrid, Spain.

ORCID-Profile: José Manuel Cameselle-Teijeiro, Iván Lesende-Rodríguez, Jorge García-González, Luis León-Mateos, María Sánchez-Ares

Förderung

  • Instituto de Salud Carlos III
  • The Health Knowledge Agency

Zitieren

APA

Abdulkader-Nallib, I., Cameselle-Teijeiro, J. M., Lesende-Rodríguez, I., Pérez-Becerra, R., Antúnez-López, J. R., García-González, J., León-Mateos, L., & Sánchez-Ares, M. (2025). Next-Generation Sequencing (NGS) in non-small cell lung carcinoma: A real-world experience in the public health system of Galicia (Northwest Spain). PLOS One. https://doi.org/10.1371/journal.pone.0326336

Vancouver

Abdulkader-Nallib I, Cameselle-Teijeiro JM, Lesende-Rodríguez I, Pérez-Becerra R, Antúnez-López JR, García-González J, et al. Next-Generation Sequencing (NGS) in non-small cell lung carcinoma: A real-world experience in the public health system of Galicia (Northwest Spain). PLOS One. 2025. doi:10.1371/journal.pone.0326336

BibTeX
@article{AbdulkaderNallib2025,
  author = {Abdulkader-Nallib, Ihab and Cameselle-Teijeiro, José Manuel and Lesende-Rodríguez, Iván and Pérez-Becerra, Raquel and Antúnez-López, José Ramón and García-González, Jorge and León-Mateos, Luis and Sánchez-Ares, María},
  title = {Next-Generation Sequencing (NGS) in non-small cell lung carcinoma: A real-world experience in the public health system of Galicia (Northwest Spain)},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0326336}
}
Kostenlos starten →